Material and Methods: The study analyzed the medical records of 37 patients who underwent Nd:YAG hyaloidotomy for premacular SHH between 2014 and 2022. Patients were evaluated based on age, gender, etiology, symptom duration, visual acuity, laser energy, number of shots, complications, and need for additional procedures. The main success criteria were drainage and absorption of SHH, increased visual acuity, need for additional procedures, and post-procedural complications.

Results: A study of 37 patients with 39 eyes, with a mean age of 52.03 ± 20.51 years and symptom duration of 10.51 ± 7.43 days, found common etiologies such as proliferative diabetic retinopathy, retinal vein occlusion, retinopathy of valsalva, leukemia, retinal macroaneurysm, hypertensive crisis, choroidal neovascular membrane, and Terson syndrome. The mean laser energy performed was 7.38 ± 2.08 mJ, and the mean number of shots was 4.28 ± 1.87. Nd:YAG laser hyaloidotomy was successful in 87.17% of cases but failed in 2 patients with proliferative diabetic retinopathy, one patient with Terson syndrome, and one patient with leukemia. Visual acuity improved significantly in the 6th month.

Conclusion: Nd:YAG laser hyaloidotomy is a cheap, effective, safe, and noninvasive treatment method for the treatment of premacular SHH. It prevents the need for invasive vitreoretinal surgery and its complications. Visual prognosis depends on the etiology of SHH and associated macular changes. Keywords : Subhyaloid, Haemorrhage, YAG, Laser, Hyaloidotomy, Surgery